Speaker illustration

Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)

Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor

Event: Heart Failure 2018 & World Congress on Acute Heart Failure

Topic: Experimental Heart Failure

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Thumbnail

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Event: ESC CONGRESS 2016

Topic: Pharmacologic therapy

Session: Heart failure / Left ventricular dysfunction

Thumbnail

This platform is supported by

logo Novo Nordisk